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Background. Circulating levels of growth factors involved in leucocyte production and angiogenesis could be indicative of underlying aberrations of tissue homeostasis and therefore be utilized as predictors of risk for all-cause cardiovascular disease (CVD) or cancer mortality.
Methods. Baseline plasma levels of a range of growth factors were measured in two cohorts of the population-based FINRISK study (1997 Discovery cohort, N = 8444, aged 25-74; 2002 Replication cohort, N = 2951, aged 51-74 years) using a multiplexed bead array methodology and ELISA. Participants were followed up by linking them to registry data.
Results. In the Discovery cohort (653 deaths; 216 CVD-related, 231 cancer-related), fully adjusted Cox proportional hazard regression models showed that increased plasma hepatocyte growth factor (HGF) and placental growth factor (PlGF) were associated with higher risk of 10-year mortality (HR, 1.29 [95% confidence interval (CI), 1.18-1.41] and HR, 1.23 [95% CI, 1.14-1.32], respectively). In the Replication cohort (259 deaths; 83 CVDrelated, 90 cancer-related), baseline HGF levels also predicted all-cause mortality (HR, 1.2 [95% CI, 1.08-1.32]; PlGF data not available). By including HGF levels in a CVD mortality model, 9% of all CVD deaths were correctly reclassified in the Discovery cohort (categorical net reclassification improvement [NRI] for events, P = 4.0 9 10
Introduction
Accurate prediction of the overall risk of death in the general population has many potential applications, including targeting of patients for preventive medical interventions. Risk factors for cardiovascular disease (CVD) mortality are well characterized, and the utility of models such as the Framingham risk score is well established. However, the utility of clinical parameters and # Equal contribution.
biomarkers for predicting all-cause and cancer mortality has not been well characterized [1, 2] ; prevalent (i.e. pre-existing) cancer, family history of cancer and smoking remain amongst the few factors that have been identified as predictors of mortality risk in different cancer types at a population level [3, 4] . Therefore, the identification of new biomarkers for early identification of increased risk of all-cause, CVD-related and cancer-related mortality remains an unmet need.
We hypothesized that the systemic levels of different growth factors may provide valuable information about deregulated tissue homeostasis. The development and maintenance of key cell populations, including hematopoietic cells and vascular endothelial cells, is strictly controlled by the availability of specific growth factors [5, 6] . Growth factors are highly potent soluble proteins that act by binding to specific receptors on corresponding cell types. In healthy adults, the turnover of different cell types varies greatly, for example hours for granulocytes, days for gut epithelial cells, months for red blood cells and years for vascular endothelial cells [5, 7] . Nevertheless, in each organ system the rate of cell disposal and renewal is precisely balanced. However, in most, if not all, disease states this delicate balance is disrupted as a result of the disease process itself (as in the case of aberrant growth factor production by tumours) or due to the reactive and restorative processes of the body (e.g. leucocytosis during infections/inflammation, revascularization of ischaemic tissues and compensation of failing organ function).
Our aim was to determine whether the circulating levels of key growth factors in a general population would be indicative of an increased mortality risk. This study was conducted using data and samples obtained from two cross-sectional population surveys from the FINRISK study. We reasoned that it would be most meaningful to focus on growth factors that exert their biological function within the vascular system. Therefore, we analysed growth factors that regulate the homeostasis of hematopoietic cells (stem cell factor [SCF], granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF]) [6] [8] . Many of these growth factors also regulate the proliferation, migration and differentiation of other cell types, such as epithelial and mesenchymal cells. We hypothesized that altered levels of hematopoietic and vascular growth factors may reflect disrupted homeostasis and thereby serve as biomarkers for increased risk of death in the general population.
Materials and methods

Study subjects
Baseline data and plasma samples were obtained from the large-scale Finnish National FINRISK study, which comprises cross-sectional population surveys that have been carried out every 5 years since 1972 to assess the risk factors of chronic diseases (e.g. CVD, diabetes, obesity and cancer) and health behaviour in the working age population. Our study population comprised two cohorts from the FINRISK study: the 1997 'Discovery' cohort (8444 subjects aged 25-74 years) and the 'Replication' cohort (a 2951-subject subpopulation of the 2002 FINRISK study consisting of subjects aged 51-74; chosen for a higher mortality rate) [9] . Both cohorts consisted of individuals who were randomly selected from the national Finnish population register and stratified to contain subjects of each sex and 10-year age group (25-34, 35-44, 45-54 , 55-64 and 65-74 years of age) from each geographic area. Due to the independent, random population sampling, 54 subjects were included by chance in both study cohorts and were surveyed 5 years apart. The two cohorts were analysed independently. Both cohorts have been described in detail elsewhere [9] . Briefly, all participants completed a health questionnaire and underwent physical examination. Subjects fasted for at least 4 h prior to blood sampling. Plasma was separated and stored at À70°C. Plasma samples were available from 7910 individuals (EDTA plasma) in the Discovery cohort, and from 2775 individuals (heparin plasma) in the Replication cohort. Participants were followed up by linking them to the National Hospital Discharge Register, National Causes of Death Register and National Drug Reimbursement Register of Finland. With the use of these national registries, follow-up of the study participants was almost 100% complete; only participants who had permanently moved away from Finland were considered lost to follow-up (~1%). Subjects in the Discovery cohort have been followed up for 15 years and participants in the Replication cohort for 10 years. All participants who died during a 10-year follow-up period were included in the 'allcause mortality' group. They were further subdivided into cause-specific categories for cardiovascular deaths (coronary heart disease [CHD] or stroke, excluding subarachnoid haemorrhage [SAH] , which has a largely different pathogenesis and risk factors) and cancer (all cancers except nonmelanoma skin cancers).
All participants provided written informed consent, and the study protocol was approved by the Coordinating Ethical Committee of the Helsinki and Uusimaa Hospital District.
Clinical and laboratory measurements
Systolic blood pressure (BP; mmHg) was measured in a sitting position using a standard mercury sphygmomanometer. Total blood cholesterol (mmol L
À1
) and high-density lipoprotein (HDL) cholesterol concentrations (mmol L À1 ) were measured at the Disease Risk Unit in the Finnish National Institute for Health and Welfare according to routine protocols. Data relating to smoking, family history of cancer and alcohol consumption were retrieved from the self-reported structured questionnaires. Prevalent diabetes, prevalent CVD and prevalent cancer diagnoses were based on registry data; self-reported diabetes at baseline was also included. The treatment data for hypertension at baseline were self-reported.
Measurement of the growth factors
The concentrations of FGF, G-CSF, GM-CSF, HGF, PDGF, SCF and VEGF were measured using multiplex technology. Custom-made multiplexed assays from Bio-Rad (for the Discovery cohort) and Bio-Rad's premixed Bio-Plex Pro Human Cytokine 27-plex Assay (catalog number: M500KCAF0Y) and 21-plex Assay (catalog number: MF0005KMII) kits (for the Replication cohort) were used. The samples had been stored at À70°C and thawed for the first time for the current analyses. The assays were performed according to the manufacturer's instructions, with the exception that the quantity of beads, detection antibodies and streptavidin-phycoerythrin conjugate was used at 50% of the recommended concentration. This was found to be sufficient in our preliminary assays and has been applied in other biomarker projects [10] [11] [12] [13] [14] [15] [16] . An eight-point standard curve using recombinant proteins was generated for each growth factor. The samples were analysed using the Bio-Plex 200 System and Bio-Plex Manager 6.0 software. The multiplex analyses were performed in a blinded manner at MediCity Research Laboratory of University of Turku. Plasma PlGF levels were measured only from the samples of Discovery cohort in the MORGAM Biomarker Laboratory by a chemiluminescent microparticle immunoassay (CMIA, Abbott, Architect i2000) [17] .
For the majority of the growth factors assessed, concentrations fell within the quantification range of the assay (Table S1 ). The notable exception was GM-CSF, from which the within-range concentrations were only available for 14% of the study subjects and were therefore excluded from all further analyses. Observations below (or above) the detection limit were extrapolated towards the asymptote of the five-parameter logistic calibration curves. Based on visual inspection, 102% of the fluorescence intensity (FI) at the lower asymptote and 98% of the FI at the upper asymptote were arbitrarily used to have some estimate of the concentrations for observations below the lower (or above the upper) detection limits [18] . Because the calibration curves were plate-specific, it was possible to obtain plate-specific estimates for the observations outside the detection limits. The values for participants without an available plasma sample were imputed using the MICE method [19] . The imputations were run for 500 iterations after a small burn-in, and finally, the data were thinned to five multiply imputed data sets.
Statistical analysis
All analyses were performed using appropriate methods for multiply imputed data (modified Rubin's rules) [20] . Rank normalized values were imputed using linear models and then transferred back to the original scale. Pregnant women were excluded from all analyses leaving 8312/8444 in the Discovery cohort and 2951/2951 in the Replication cohort. A 10-year follow-up time was used in all analyses. Continuous baseline characteristics are provided as a median and interquartile range (IQR). Categorical variables are shown as percentages. The t-test and the chi-square test were used to compare the values of the deceased and alive populations.
To estimate the predictive value of growth factors to different end-points, multivariate Cox proportional hazard models were compiled, with age as the timescale. Continuous variables were log-transformed prior to testing. The fully adjusted, sex-stratified model for 'all-cause mortality' included area of residence, smoking times per day, years of regular smoking, alcohol consumption, blood total and HDL cholesterol levels, systolic BP, prevalent CVD, prevalent cancer and prevalent diabetes; each growth factor was entered into the model individually. The sex-stratified model for 'CVD mortality' included area of residence, total and HDL cholesterol, systolic BP, hypertension treatment, current smoking, and prevalent diabetes, and each growth factor entered individually. The fully adjusted, sex-stratified model for 'cancer mortality' included smoking times per day, years of regular smoking and family history of cancer. The hazard ratios (HR) and their 95% confidence limits (Cl) are shown for growth factors as 1-SD change of the log-transformed values. The Cox proportional hazards assumptions were tested by the R-function cox.zph(), and all models were valid.
Weibull regression with age as the timescale was used to predict the 10-year absolute risk. C-index improvement (C-statistic), integrated discrimination improvement (IDI) and net reclassification improvement (NRI) analyses were used to test the discrimination and reclassification ability of the models. Conventional categorical NRI (subjects at <5%, 5-20% and >20% risk of death within the next 10 years) was used. In addition, clinical NRI was used, which estimates NRI for those subjects who are at intermediate risk (10-year absolute risk, 5-20%) based on the traditional risk model [21] . In NRI analyses, the results are shown for accurate reclassifications 1) amongst all participants (all), 2) amongst participants who died during the followup time (events) and 3) amongst participants who survived for 10 years (nonevents). Ten-fold crossvalidation was used to control for overoptimism due to using the same model for fitting and prediction. The partition of the data for the 10-fold cross-validation was end-point-specific based on random sampling stratified by the end-point status, sex and 10-year age group and was kept the same throughout the study to obtain comparable results.
Finally, results of the Discovery cohort and the Replication cohort were combined using an inversevariance weighted meta-analysis. Random-effects meta-analysis was used when the heterogeneity (as measured by I 2 ) was ≥0.5, and fixed-effects metaanalysis was applied otherwise.
Results
Baseline characteristics of the study population
After exclusions, the Discovery cohort consisted of 8312 participants (age range, 25-74 years; 49.6% female) and the Replication cohort consisted of 2951 participants (age range, 51-74 years; 51.4% female). Pregnant women were excluded from the analyses as pregnancy had a substantial influence on circulating growth factor levels (data not shown). The follow-up was censored at 10 years in all analyses. During the follow-up, there were 653 deaths in the Discovery cohort, of which 216 were due to CVD and 231 were due to cancer. In the Replication cohort, the numbers of the allcause, CVD and cancer deaths were 259, 83 and 90, respectively.
The baseline laboratory and clinical parameters used to assess the risk of CVD and cancer in the Discovery cohort are shown in Table 1 ; data for the Replication cohort are shown in Table S2 . At baseline, the participants of the Discovery cohort who died from any cause during the follow-up time were older, had higher BP, higher total cholesterol and lower HDL cholesterol, were more often smokers, had higher levels of antihypertensive medication use and had lower levels of alcohol consumption than those who were alive at the end of the follow-up period. They also had a higher prevalence of CVD, cancer, family history of cancer and diabetes. Those participants who died due to CVD also differed from survivors in these parameters, with the exception of smoking status and alcohol consumption. When compared with survivors, the subjects who died of cancer differed in the same parameters as those in the all-cause mortality group, with the exception of total cholesterol values, which did not differ. In the Replication cohort, the risk parameters differentiating the nonsurvivors from survivors in the all-cause and CVD death groups were in general similar to those in the Discovery cohort, although the differences in the absolute values were lower (Table S2) .
Baseline circulating growth factor levels amongst the survivors and nonsurvivors
In the Discovery cohort, subjects who were still alive after 10 years of follow-up had significantly lower levels of HGF (median level, 16.4% lower) and PlGF (median level, 19.2% lower) at baseline than those who died during the follow-up period Growth factors and mortality / K. Santalahti et al.
( Table 1) . HGF levels were also significantly lower amongst the survivors in the Replication cohort (median level, 13.5% lower; Table S2 ).
In the analysis of cause-specific mortality, we found higher baseline concentrations of HGF and PlGF amongst those who died of CVD than in the survivors in the Discovery cohort ( Table 1 ). The levels of these two growth factors were also increased in the group of cancer deaths when compared with the survivors (Table 1 ). In the Replication cohort, increased HGF levels were found both amongst those who died of CVD and those who died of cancer (Table S2 ). The levels of the other five growth factors were not consistently different between the survivors and nonsurvivors in the two cohorts, with the exception of a small increase in SCF levels in the subgroup of individuals whose deaths were CVD-related (Table 1 and Table S2 ). These data suggest that HGF and PlGF levels are selectively increased in subjects who are at a substantial risk of dying within the next 10 years.
Growth factors in the estimation of the risk of all-cause mortality
We hypothesized that the major known risk factors for CVD and cancer, or these diseases in a prevalent form, are likely to be the major contributors to all-cause mortality at the population level. In Cox's regression models, more frequent smoking, more years of regular smoking, lower alcohol consumption (Discovery cohort only), high systolic BP (Replication cohort only), low HDL, living in the Eastern part of Finland, and prevalence of CVD, cancer and diabetes were associated with an increased risk of all-cause death (data not shown).
To study the association of plasma growth factor levels with all-cause mortality, each growth factor was included in the fully adjusted reference model. High plasma HGF and PlGF concentrations, but not those of the five other growth factors, were associated with a high risk for all-cause mortality.
In the Discovery cohort, a 1-SD increase in the natural logarithm of HGF and PlGF levels increased the risk of any death by 29% (P = 5.3 9 10
À6
) and 23% (P = 5.2 9 10
À7
), respectively (Table 2) . HGF was also significantly associated with the overall risk of death in the Replication cohort, in which a 1-SD increase in the natural logarithm of HGF plasma concentrations accounted for a 20% increase in the risk of death (Table 3) . When the two distinct cohorts were pooled in a meta-analysis, HGF remained an independent predictor of all-cause mortality (Table 3) . Furthermore, an association of high VEGF levels with a high risk of all-cause mortality became evident in the meta-analysis (Table 3) . Therefore, plasma HGF and PlGF (and possibly VEGF) concentrations have the potential to serve as new, independent, risk factors for predicting the 10-year mortality at a population level.
Growth factors in the risk estimation of CVD mortality
In the Discovery cohort, a 1-SD increment in the natural logarithm of HGF or PlGF concentration increased the risk of death from CVD by 33% (P = 9.9 9 10
À6
) and 21% (P = 0.0086), respectively, in a fully adjusted model ( Table 2 ). The same tendency for HGF was seen in the Replication cohort (HR, 1.14), but the association was not statistically significant (Table 3 ). In a meta-analysis consisting of both cohorts, a high HGF level predicted a high risk of CVD death (HR, 1.27; P = 2.3 9 10
; Table 3 ). In addition, high SCF levels were also weakly associated (HR, 1.12, P = 0.033) with CVD-related deaths in the metaanalyses (Table 3 ). There was no association between the plasma levels of other growth factors and CVD death in either cohort or in the metaanalyses of the cohorts. Therefore, plasma HGF and PlGF (and possibly SCF) appear to be independent prognostic factors for 10-year CVD mortality in this general population.
Growth factors in the risk estimation of cancer mortality
In the Discovery study, a 1-SD increase in PlGF levels accounted for a 23% (P = 4.7 9 10 À4 ) increase in the hazard for cancer-related death in a fully adjusted model (Table 2) . HGF levels predicted a high risk of death due to cancer only in a meta-analysis (HR, 1.14; P = 0.019; Table 3 ). The risk of death from cancer did not associate with the plasma levels of any of the other five growth factors investigated in any of the analyses. Therefore, although there was only a limited statistical power due to the relatively small numbers of cancerspecific deaths, our analyses suggest that levels of circulating PlGF, and possibly HGF, are potential independent predictors for 10-year mortality from cancer.
Sensitivity analysis
To study the association of existing disease processes with growth factors and the risk of 10-year mortality, we performed two types of sensitivity analyses: the first excluded prevalent cases from each death category, and the second excluded the prevalent cases and all incident cases taking place during the first 5 years of follow-up. In both sensitivity analyses, the results for HGF remained essentially unchanged when compared with those without these exclusions (Tables S3, S4 ). For PlGF, the exclusion of prevalent cases did not alter the results, whereas exclusion of the prevalent cases and the events during the first 5 years diminished the predictive value of this biomarker (Tables S3,  S4 ).
Performance of the mortality prediction models after inclusion of HGF and PlGF
To estimate the ability of HGF and PlGF to improve the risk discrimination and reclassification performance of the mortality models in a general population, we included these two growth factors in the 10-fold cross-validated Weibull models adjusted for the traditional risk factors. In the Discovery cohort, inclusion of either HGF or PlGF resulted in a small but statistically significant improvement in the C-statistic for the discrimination of the allcause and CVD-specific mortality outcome; PlGF also improved the C-statistic for the cancer mortality model (Table 4 ). In the Replication cohort, plasma HGF concentration improved the performance of the all-cause mortality model, and in the meta-analyses, it improved the discrimination of both all-cause and CVD-specific mortality (Table 4) . Inclusion of HGF in the mortality models also improved the IDI for all-cause and CVDspecific mortality in the Discovery cohort and in the meta-analyses (Table 4) . The plasma PlGF level improved IDI for the all-cause mortality and cancer mortality (Table 4 ).
In the categorical NRI analysis (<5%, 5-20% and >20% risk of death), inclusion of HGF improved the model's sensitivity by correctly reclassifying 8.7% of the CVD mortality cases. In addition, the specificity of the all-cause and CVD mortality models was improved as inclusion of HGF improved the reclassification of the nonevents in the Discovery and pooled analyses. The clinical NRI focuses on the reclassification of the clinically relevant intermediate-risk group (5-20% 10 year absolute risk of death). When HGF levels were added as predictors in all-cause and CVD-specific mortality models, improvements in clinical NRI were evident for both events and nonevents. This resulted in relatively high overall NRIs (0.10-0.18) in the Discovery cohort and in the meta-analyses (Table 4) . PlGF improved the performance of the categorical NRI models predicting the risk of CVD-specific deaths amongst the nonevents and all participants, and that of all-cause mortality amongst the nonevents (Table 4) . PlGF also improved the reclassification of the intermediate-risk group for all-cause mortality, CVD mortality and cancer mortality amongst the nonevents, and for all-cause mortality and CVD Fully adjusted sex-stratified model for all-cause mortality: geographic region, smoking times per day, years of regular smoking, alcohol consumption, total cholesterol, HDL cholesterol, systolic blood pressure, prevalent CVD, prevalent cancer, prevalent diabetes and growth factor. b Fully adjusted sex-stratified model for CVD mortality: geographic region, log(total cholesterol), log(HDL cholesterol), log(systolic blood pressure), hypertension treatment, current smoking, prevalent diabetes, prevalent CVD and growth factor. (Table 4) .
Discussion and Conclusion
Analysis of serum samples from over 10 000 individuals demonstrated that the plasma levels of two growth factors, HGF and PlGF, are independent predictors of 10 year all-cause, CVD and cancer mortality in our study cohort, which is representative of the general population. Inclusion of HGF and PlGF in the fully adjusted mortality models improved the predictive power of the models when assessed by three different approaches (C-statistic, NRI and IDI) when analysing cohorts with an adequate numbers of events. HGF levels improved the reclassification of all participants falling into the intermediate-risk group for all-cause and CVD mortality (i.e. clinical NRI). Therefore, HGF and PlGF may serve as novel biomarkers that could be utilized in mortality risk stratification. This may have clinical implications by prompting targeted preventive measures to be put in place in individuals who are at the greatest risk of a fatal outcome during the next 10 years.
HGF and PlGF are both involved in angiogenesis.
PlGF is not only secreted by the placenta, but also produced in adult tissues including cardiac endothelial cells [22] ; it binds to VEGFR-1 on endothelial cells to mediate angiogenic effects. Genetic or pharmacologic ablation of PlGF is seen to inhibit intimal thickening and macrophage accumulation in mouse models [23, 24] . In some animal models, inhibition of PlGF has also been shown to dramatically reduce or even regress tumour growth and metastasis [25] . HGF is produced by many cell types and signals via the c-met receptor [26, 27] . HGF is also essential for epithelial morphogenesis, tissue protection, and regeneration by providing pro-proliferative, promigratory, anti-apoptotic, anti-inflammatory and antifibrotic signals to several cell types. The role of soluble HGF and PlGF levels in predicting mortality in a general population has not been studied in detail. In an exploratory time-to-event analysis using a nested case-controlled approach within the Nurses' Health Study, the highest plasma PlGF quintile was independently associated with risk of CHD, when measured >10 years before the event [28] . In a second study of 1200 apparently healthy Japanese subjects, serum HGF levels were higher in those who died during the 10-year follow-up, and HGF was seen to be Table 3 Fully adjusted hazard ratios for all-cause, CVD and cancer deaths in Replication population and meta-analysis of the two studies Fully adjusted sexstratified model for CVD mortality: geographic region, log(total cholesterol), log(HDL cholesterol), log(systolic blood pressure), hypertension treatment, current smoking, prevalent diabetes, prevalent CVD and growth factor. Table 4 Performance metrics of HGF and PlGF in risk prediction models of all-cause, CVD and cancer mortality Fully adjusted sex-stratified model for CVD mortality: geographic region, log(total cholesterol), log(HDL cholesterol), log(systolic blood pressure), hypertension treatment, current smoking, prevalent diabetes, prevalent CVD and growth factor. Growth factors and mortality / K. Santalahti et al.
an independent predictor of all-cause and cancer death [29] .
Analyses of the predictive value of PlGF and HGF levels for relatively short-term survival in different common CVD and cancer outcomes show conflicting results. High PlGF levels have been reported to predict the development of major adverse cardiac events (MACE) in patients with acute coronary syndrome [30, 31] , and high mortality in patients with suspected acute myocardial infarction [32] , chronic kidney disease [33] and normoalbuminuric type 1 diabetes [34] . However, other studies show soluble PlGF levels to have no predictive value when assessing CVD mortality in patients with coronary artery disease [35] , or when assessing adverse outcomes in patients with heart failure [36, 37] . High blood PlGF levels have been shown to predict a favourable long-term function of the heart after acute myocardial infarction [38] . In cancer, PlGF is often overexpressed, and high tumour PlGF levels have been associated with short survival times in breast [39] and colorectal [40] cancers. By contrast, HGF is an independent predictor of mortality in chronic and acute heart failure [41] [42] [43] [44] . Although HGF has been shown to be protective in myocardial infarction [45] , high levels of soluble HGF have also been reported to be a marker of arteriosclerosis [46] and acute myocardial infarction [47] , and to be associated with poor prognosis in acute coronary syndromes [48] . In some types of cancer, high serum HGF levels correlate with advanced tumours and are an independent prognostic marker for poor survival in cancers such as colorectal and non-small-cell lung adenocarcinoma [49] [50] [51] .
Our findings strongly suggest that high plasma levels of PlGF and HGF in the general population are predictive of mortality during the following 10 years. We speculate that the adverse effects of high PlGF and HGF levels may be associated with underlying disease, which may reflect tissue hypoxia and/or neoangiogenesis (e.g. ischaemiainduced angiogenesis in tumours or atherosclerotic vessels). This hypothesis is supported by the finding that VEGF, a key angiogenic cytokine, became predictive of all-cause and cancer mortality in the meta-analyses.
We found that PlGF and HGF are predictive of both CVD and cancer deaths, although it is possible that underlying pathological conditions may have already been initiated in many of those who died early on in the follow-up period even though the clinical diagnoses had not yet been established. However, sensitivity analysis did not support this possibility as exclusion of the prevalent cases did not change the results in any of the death groups. Therefore, our findings are consistent with observations that high levels of PlGF and HGF are associated with poor outcomes in patients with different common CVDs and malignancies. Therefore, HGF and PlGF levels may be useful biomarkers, identifying individuals who may have ongoing, life-threatening, but subclinical disease processes, or tissue hypoxia, which could potentially be treated with early medical intervention or lifestyle changes.
We acknowledge that this study has certain limitations. Although prospective, it is an observational study with a single blood sample from each subject. Therefore, any causal conclusions between the increased growth factor levels and mortality cannot be drawn. In addition, we used a multiplexed technology for evaluating several different growth factors at the same time. Although the measured levels of HGF and PlGF were comparable to those obtained with more traditional high-sensitivity ELISAs, the detection levels for some growth factors, such as GM-CSF, were suboptimal using this technology. Moreover, it became apparent that the measurable levels of the growth factors in blood samples differ with different anticoagulants (EDTA plasma in the Discovery and heparin plasma in the Replication cohort) and with different lots of the kits, which made comparisons of the absolute values in the two cohorts impossible. Storage time and number of thawing cycles may affect the concentrations of biomarkers, but the potential effects of these variables were minimized using samples that had been collected during 3-month periods in 1997 and 2002, maintained at À70°C and thawed for the first time immediately prior to cytokine measurements. Another potential limitation arises from the knowledge that incorporation of new biomarkers into original Cox regression models with a very good initial discriminatory power (e.g. all-cause mortality C-statistic 0.8) results in difficulty in obtaining meaningfully larger C-statistic values. Therefore, the use of three additional measures of improved discriminative and predictive ability (IDI, categorical NRI and clinical NRI) has become increasingly popular [52] . In particular, the clinical NRI reclassifies individuals in the intermediate-risk category to the low-and high-risk categories [21] . These are the subjects who would benefit most from more accurate risk prediction, allowing preventive measures to be targeted to those who are indeed at high risk but are not detected using the traditional risk estimates. Therefore, it was notable that both HGF and PlGF improved the clinical NRI for all-cause and CVD mortality amongst all participants and that HGF improved clinical NRI for these two death categories even amongst the events. These parameters also indicated the independent capacity of HGF and PlGF to predict mortality. However, recent literature indicates that reclassification measures have certain limitations for measuring predictive performance [53, 54] . To account for these potential issues, we used cross-validation to minimize the risk of overoptimistic interpretation of the reclassification results. More importantly, we only performed NRI analyses for those growth factors that had significant predictor P-values in the Cox model, the calibration of which was checked with the Hosmer-Lemeshow test. Another limitation is that the number of events (i.e. deaths) is unavoidably small in the general population, and may undermine the statistical robustness of the analyses, as we observed with the Replication cohort. Finally, our observations were made in a genetically homogenous Caucasian population, and their validity in other populations would need to be determined by future studies.
In conclusion, increased plasma levels of HGF and PlGF are seen to be independent risk factors for allcause CVD and cancer mortality in this general population, even when the models are adjusted for prevalent CVD and cancer, as well as other commonly accepted risk factors. The inclusion of these two multifunctional growth factors in mortality prediction models improved the predictive power and improved the stratification of subjects to categorical and clinically relevant groups with different mortality risks. The possible clinical potential of utilizing plasma HGF and PlGF levels to identify apparently healthy individuals with an intermediate risk (5-20%) of death during the next 10 years in a general population warrants further investigation.
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